UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 252

Sortiert nach

A Pilot Study of the Telomerase Inhibitor Imetelstat for Myelofibrosis

The New England journal of medicine, 2015-09, Vol.373 (10), p.908-919

2015

Volltextzugriff (PDF)

Risk of QTc prolongation among cancer patients treated with tyrosine kinase inhibitors

International journal of cancer, 2020-12, Vol.147 (11), p.3160-3167

2020

Volltextzugriff (PDF)

DIPSS Plus: A Refined Dynamic International Prognostic Scoring System for Primary Myelofibrosis That Incorporates Prognostic Information From Karyotype, Platelet Count, and Transfusion Status

Journal of clinical oncology, 2011-02, Vol.29 (4), p.392-397

2011

Volltextzugriff (PDF)

Tyrosine kinase inhibitors dosing for chronic phase chronic myeloid leukemia: The case for starting low with dasatinib (50 mg/day) and ponatinib (15 mg/day)

American journal of hematology, 2022-11, Vol.97 (11), p.1394-1397

2022

Volltextzugriff (PDF)

Venetoclax and hypomethylating agents in acute myeloid leukemia: Mayo Clinic series on 86 patients

American journal of hematology, 2020-12, Vol.95 (12), p.1511-1521

2020

Volltextzugriff (PDF)

3023 Mayo Clinic Patients With Myeloproliferative Neoplasms: Risk-Stratified Comparison of Survival and Outcomes Data Among Disease Subgroups

Mayo Clinic proceedings, 2019-04, Vol.94 (4), p.599-610

2019

Volltextzugriff (PDF)

Predictors of anemia response to momelotinib therapy in myelofibrosis and impact on survival

American journal of hematology, 2023-02, Vol.98 (2), p.282-289

2023

Volltextzugriff (PDF)

Intravenous Bevacizumab for Refractory Hereditary Hemorrhagic Telangiectasia–Related Epistaxis and Gastrointestinal Bleeding

Mayo Clinic proceedings, 2018-02, Vol.93 (2), p.155-166

2018

Volltextzugriff (PDF)

One Thousand Patients With Primary Myelofibrosis: The Mayo Clinic Experience

Mayo Clinic proceedings, 2012, Vol.87 (1), p.25-33

2012

Volltextzugriff (PDF)

Daratumumab and brentuximab vedotin combination therapy in T-cell acute lymphoblastic leukemia refractory to conventional chemotherapy and allogeneic stem cell transplant

Haematologica (Roma), 2024-02, Vol.109 (2), p.689

2024

Volltextzugriff (PDF)

Determinants of survival and retrospective comparisons of 183 clinical trial patients with myelofibrosis treated with momelotinib, ruxolitinib, fedratinib or BMS- 911543 JAK2 inhibitor

Blood cancer journal (New York), 2023-01, Vol.13 (1), p.3-3, Article 3

2023

Volltextzugriff (PDF)

Clinical Heterogeneity of the VEXAS Syndrome: A Case Series

Mayo Clinic proceedings, 2021-10, Vol.96 (10), p.2653-2659

2021

Volltextzugriff (PDF)

Venetoclax with azacitidine or decitabine in blast‐phase myeloproliferative neoplasm: A multicenter series of 32 consecutive cases

American journal of hematology, 2021-07, Vol.96 (7), p.781-789

2021

Volltextzugriff (PDF)

Sodium‐glucose co‐transporter‐2 inhibitor use and JAK2 unmutated erythrocytosis in 100 consecutive cases

American journal of hematology, 2023-07, Vol.98 (7), p.E165-E167

2023

Volltextzugriff (PDF)

Granularity in disease classification impacts survival prediction in advanced systemic mastocytosis: A single institution study of 329 informative cases

American journal of hematology, 2024-01, Vol.99 (1), p.21-27

2024

Volltextzugriff (PDF)

Cardiac events in newly diagnosed acute myeloid leukaemia during treatment with venetoclax + hypomethylating agents

British journal of haematology, 2024-04, Vol.204 (4), p.1232-1237

2024

Volltextzugriff (PDF)

Clinicopathologic correlates and prognostic impact of lymphoid aggregates in patients with myelodysplastic syndromes

British journal of haematology, 2024-07

2024

Volltextzugriff (PDF)

One thousand patients with essential thrombocythemia: the Mayo Clinic experience

Blood cancer journal (New York), 2024-01, Vol.14 (1), p.11-11, Article 11

2024

Volltextzugriff (PDF)

Limited activity of luspatercept in myelofibrosis and myeloid neoplasms other than myelodysplastic syndromes with ring sideroblasts

American journal of hematology, 2022-12, Vol.97 (12), p.E474-E477

2022

Volltextzugriff (PDF)

Momelotinib for myelofibrosis: 12‐year survival data and retrospective comparison to ruxolitinib

American journal of hematology, 2022-12, Vol.97 (12), p.E433-E435

2022

Volltextzugriff (PDF)

Targeted next-generation sequencing in blast phase myeloproliferative neoplasms

Blood advances, 2018-02, Vol.2 (4), p.370-380

2018

Volltextzugriff (PDF)

Cladribine therapy for advanced and indolent systemic mastocytosis: Mayo Clinic experience in 42 consecutive cases

British journal of haematology, 2022-02, Vol.196 (4), p.975-983

2022

Volltextzugriff (PDF)

Adverse karyotype subcategories in acute myeloid leukemia display significant differences in mutation composition and transplant-augmented survival

Haematologica (Roma), 2023-01, Vol.108 (1), p.245

2023

Volltextzugriff (PDF)

Acute coronary syndromes in patients with active hematologic malignancies – Incidence, management, and outcomes

International journal of cardiology, 2019-01, Vol.275, p.6-12

2019

Volltextzugriff (PDF)

1 – 25 von 252

Suche als RSS-Feed

Aktive Filter

KollektionNexis

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(250)
Mit Volltextzugriff
(245)

Publikationsform

Artikel
(251)
Berichte
(1)

Sprache

Englisch
(252)
Japanisch
(8)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

Menü

Weitere Dienste

Einstellungen

A Pilot Study of the Telomerase Inhibitor Imetelstat for Myelofibrosis

Risk of QTc prolongation among cancer patients treated with tyrosine kinase inhibitors

DIPSS Plus: A Refined Dynamic International Prognostic Scoring System for Primary Myelofibrosis That Incorporates Prognostic Information From Karyotype, Platelet Count, and Transfusion Status

Tyrosine kinase inhibitors dosing for chronic phase chronic myeloid leukemia: The case for starting low with dasatinib (50 mg/day) and ponatinib (15 mg/day)

Venetoclax and hypomethylating agents in acute myeloid leukemia: Mayo Clinic series on 86 patients

3023 Mayo Clinic Patients With Myeloproliferative Neoplasms: Risk-Stratified Comparison of Survival and Outcomes Data Among Disease Subgroups

Predictors of anemia response to momelotinib therapy in myelofibrosis and impact on survival

Intravenous Bevacizumab for Refractory Hereditary Hemorrhagic Telangiectasia–Related Epistaxis and Gastrointestinal Bleeding

One Thousand Patients With Primary Myelofibrosis: The Mayo Clinic Experience

Daratumumab and brentuximab vedotin combination therapy in T-cell acute lymphoblastic leukemia refractory to conventional chemotherapy and allogeneic stem cell transplant

Determinants of survival and retrospective comparisons of 183 clinical trial patients with myelofibrosis treated with momelotinib, ruxolitinib, fedratinib or BMS- 911543 JAK2 inhibitor

Clinical Heterogeneity of the VEXAS Syndrome: A Case Series

Venetoclax with azacitidine or decitabine in blast‐phase myeloproliferative neoplasm: A multicenter series of 32 consecutive cases

Sodium‐glucose co‐transporter‐2 inhibitor use and JAK2 unmutated erythrocytosis in 100 consecutive cases

Granularity in disease classification impacts survival prediction in advanced systemic mastocytosis: A single institution study of 329 informative cases

Results of a randomized phase 3 study of oral sapacitabine in elderly patients with newly diagnosed acute myeloid leukemia (SEAMLESS)

Cardiac events in newly diagnosed acute myeloid leukaemia during treatment with venetoclax + hypomethylating agents

Clinicopathologic correlates and prognostic impact of lymphoid aggregates in patients with myelodysplastic syndromes

One thousand patients with essential thrombocythemia: the Mayo Clinic experience

Limited activity of luspatercept in myelofibrosis and myeloid neoplasms other than myelodysplastic syndromes with ring sideroblasts

Momelotinib for myelofibrosis: 12‐year survival data and retrospective comparison to ruxolitinib

Targeted next-generation sequencing in blast phase myeloproliferative neoplasms

Cladribine therapy for advanced and indolent systemic mastocytosis: Mayo Clinic experience in 42 consecutive cases

Adverse karyotype subcategories in acute myeloid leukemia display significant differences in mutation composition and transplant-augmented survival

Acute coronary syndromes in patients with active hematologic malignancies – Incidence, management, and outcomes

Aktive Filter

Suchergebnisse filtern